JAC Advance Access originally published online on June 9, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(1):144-154; doi:10.1093/jac/dkh298
JAC vol.54 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
1The JONES Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317; 2Tufts University School of Medicine, Boston, MA, USA
* Corresponding author. Tel: +1-319-665-3370; Fax: +1-319-665-3371; Email: ronald-jones{at}jmilabs.com
Objectives: To investigate the potency of doripenem, a broad-spectrum carbapenem characterized by a wider spectrum of activity combining antimicrobial and bactericidal features of imipenem and meropenem.
Methods: This parenteral compound was studied against recent clinical isolates (2001–2002) from a worldwide organism collection. A total of 902 strains were susceptibility tested by reference methods against doripenem and six to 28 comparators including ertapenem, imipenem and meropenem. The organisms tested included: Enterobacteriaceae (281 strains), Acinetobacter spp. (33), Pseudomonas aeruginosa (35), Stenotrophomonas maltophilia (36), other non-fermenters (22), Haemophilus influenzae (61), Moraxella catarrhalis (33), oxacillin-susceptible staphylococci (39), enterococci (84), streptococci (163), various anaerobes (98), and other Gram-positive species such as Corynebacterium and Bacillus spp. (17).
Results: Against Enterobacteriaceae, the average doripenem MIC90 was 0.03 mg/L (range, 
0.015–0.25 mg/L). Doripenem was two- to 16-fold more potent than imipenem and comparable to ertapenem and meropenem; all doripenem MIC values with enteric bacilli were 4 mg/L. Doripenem was active against Aeromonas (MIC50, 0.03 mg/L), Bacillus spp. (MIC50, 0.03 mg/L) and all tested anaerobic species (MIC range, 0.015–4 mg/L), but was less active against S. maltophilia (MIC90, >32 mg/L) and Enterococcus faecium (MIC90, >32 mg/L) among the enterococcal species. Time-dependent bactericidal action was observed for doripenem and broth MIC results were slightly greater when compared to agar MIC results. In pilot testing, the optimal doripenem disc concentration was 10 µg, identical to standardized reagents for other clinically available carbapenems.
Conclusions: Doripenem appears to be a potent carbapenem with a spectrum resembling currently marketed antipseudomonal carbapenems, but with greater activity when tested against some non-fermentative bacillary strains. Continued evaluation of doripenem against isolates resistant to other ß-lactams appears to be warranted.
Keywords: resistance , broad-spectrum , ß-lactams , MBC , susceptibility testing
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. L. Crandon, C. C. Bulik, and D. P. Nicolau In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4352 - 4356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Naber, L. Llorens, K. Kaniga, P. Kotey, D. Hedrich, and R. Redman Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3782 - 3792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. El Solh and A. Alhajhusain Update on the treatment of Pseudomonas aeruginosa pneumonia J. Antimicrob. Chemother., August 1, 2009; 64(2): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cirillo, N. Vaccaro, K. Turner, B. Solanki, J. Natarajan, and R. Redman Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers J. Clin. Pharmacol., July 1, 2009; 49(7): 798 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Pillar, M. K. Torres, N. P. Brown, D. Shah, and D. F. Sahm In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4388 - 4399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kim, M. A. Banevicius, and D. P. Nicolau In Vivo Pharmacodynamic Profiling of Doripenem against Pseudomonas aeruginosa by Simulating Human Exposures Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2497 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Davies, W. Shang, K. Bush, and R. K. Flamm Activity of doripenem and comparator {beta}-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x J. Antimicrob. Chemother., March 1, 2008; 61(3): 751 - 753. [Full Text] [PDF]
|
|
|
|
|
|
K. L. Credito, L. M. Ednie, and P. C. Appelbaum Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis Antimicrob. Agents Chemother., January 1, 2008; 52(1): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ikawa, N. Morikawa, N. Urakawa, K. Ikeda, H. Ohge, and T. Sueda Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients J. Antimicrob. Chemother., December 1, 2007; 60(6): 1395 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo Global Challenge of Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Krueger, J. Bulitta, M. Kinzig-Schippers, C. Landersdorfer, U. Holzgrabe, K. G. Naber, G. L. Drusano, and F. Sorgel Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1881 - 1889. [Abstract] [Full Text] [PDF]
|
|